Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

"It must be balanced against the burn rate to ensure Advaxis doesn't screw over existing shareholders by dilution. Seems like a balancing act for sure. Hope DO's up to the task...."

With all due respect MP, given the price we are at now relative to the $12 recapitalization of the company over the last four years and all the dilutive capital raises plus large dilutive share grants to fund management bonuses despite lack of shareholder performance, I think "to date" the facts are that DO's balancing act has been more on the side of screwing existing shareholders. I am hopeful that will change, as his recent interview was very encouraging and reading between the lines I think we could see some big upcoming developments that take us back to more of a higher fair valuation.